Background: Bortezomib is an anti-neoplastic drug acting against multiple myeloma but its
use is associated with the onset of painful peripheral neuropathy. Tumor necrosis factor-α …

Bortezomib is a proteasome inhibitor showing strong antitumor activity against many tumors,
primarily multiple myeloma. Bortezomib-induced neuropathic pain is the main side effect …

Bortezomib, an effective anticancer drug for multiple myeloma, often causes peripheral
neuropathy which is mainly characterized by numbness and painful paresthesia …

Background/Aims: Bortezomib (BTZ) is largely used as a chemotherapeutic agent for the
treatment of multiple myeloma. However, one of the significant limiting complications of BTZ …

Bortezomib (BTZ) is used as a chemotherapeutic agent for the treatment of multiple
myeloma. Nevertheless, one of the significant limiting complications of BTZ is painful …

Bortezomib, an inhibitor of proteasome holoenzyme, is used to treat relapsed and refractory
multiple myeloma. Peripheral neuropathy is a treatment-limiting adverse effect of bortezomib …

Bortezomib (BTZ) is generally used as a chemotherapeutic agent for the treatment of
multiple myeloma; however, one of the significant limiting complications of BTZ is painful …

Background and Purpose Bortezomib (Velcade®) is a breakthrough treatment for multiple
myeloma, significantly improving patient survival. However, its use is limited by painful …

Purpose Bortezomib, a proteasome inhibitor drug very effective against multiple myeloma,
may induce the so-called bortezomib-induced peripheral neuropathy (BIPN), hardly …

Neurotoxicity towards the peripheral nervous system which appears clinically in the form of
painful neuropathy is an essential dose-limiting factor during the treatment of multiple …